To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes

NCT07539259 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

445

Enrollment

OTHER

Sponsor class

Conditions

Aortic Stenosis

Interventions

DRUG: Dapagliflozin (DAPA)
DRUG: Spironolactone (drug)
DRUG: Spironolactone + Dapagliflozin
DRUG: Epleronone

Sponsor

University College, London